Show simple item record

dc.contributor.authorClaeson, M.
dc.contributor.authorBaade, P.
dc.contributor.authorMarchetti, M.
dc.contributor.authorBrown, S.
dc.contributor.authorSoyer, H. P.
dc.contributor.authorSmithers, B. M.
dc.contributor.authorGreen, Adèle C
dc.contributor.authorWhiteman, D. C
dc.contributor.authorKhosrotehrani, K.
dc.date.accessioned2021-07-19T10:28:52Z
dc.date.available2021-07-19T10:28:52Z
dc.date.issued2021en
dc.identifier.citationClaeson M, Baade P, Marchetti M, Brown S, Soyer HP, Smithers BM, et al. Comparative performance of predictors of death from thin (≤1.0 mm) melanoma. British Journal of Dermatology. 2021 May 12.en
dc.identifier.pmid33982292en
dc.identifier.doi10.1111/bjd.20480en
dc.identifier.urihttp://hdl.handle.net/10541/624126
dc.description.abstractDespite overall favourable prognosis,1 thin (≤1.0 mm) cutaneous melanoma account for 23% of melanoma deaths in the high-risk general population of Queensland, Australia (2005-2009), because of the sheer volume of disease.2 The prospect of adjuvant systemic therapy has increased the focus on identifying patients with thin melanoma who are at high risk of death, such as through gene expression profiling (GEP), sentinel lymph node biopsy (SLNB), or prognostic models.3-5.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1111/bjd.20480en
dc.titleComparative performance of predictors of death from thin (≤1.0 mm) melanomaen
dc.typeOtheren
dc.contributor.departmentDepartment of Population Health, QIMR Berghofer Medical Research Institute, Brisbane, Australia.en
dc.identifier.journalBritish Journal of Dermatologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record